News

Levosimendan Aids Kidneys in PH Patients with Heart Disease and Renal Impairment, Phase 3 Data Show

Levosimendan, an investigational therapy for pulmonary hypertension associated with heart failure and preserved ejection fraction (PH-HFpEF), was found to improve workings of the kidneys in PH-HFpEF patients with kidney impairment in a Phase 3 clinical trial. Findings from the study, “Differential effects of levosimendan and dobutamine on glomerular…

Investigational Extended-Release Ralinepag for PAH Treatment Shows Favorable Results in Phase 1 Trials

Extended-release tablets of ralinepag, Arena Pharmaceuticals’ treatment candidate for pulmonary arterial hypertension (PAH), show a superior pharmacokinetic profile over both immediate-release ralinepeg capsules and approved immediate-release medication Uptravi (selexipag), according to two Phase 1 trials in healthy volunteers. Pharmacokinetics (PK) refer to how a drug is absorbed,…

Higher Concentration of Inhaled Ventavis May Help PAH Patients Stick to Treatment, Study Suggests

More pulmonary arterial hypertension (PAH) patients were able to achieve complete daily inhalations after switching to a more concentrated formulation of Ventavis (iloprost), which also reduced the duration of each treatment administration, an observational study reports. The study looked at the inhalation behavior of PAH patients who were switched from…